ArticlePLoS genetics2014
Lack of replication of the GRIN2A-by-coffee interaction in Parkinson disease.
Open access · goldAbstract read
In one paragraph
Article in PLoS genetics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Pooled analysis of the HLA-DRB1 by smoking interaction in Parkinson disease.Annals of neurology · 2017Pooled it
- Lifestyle medicine for neuroprotection: evidence and implementation in Asian contexts.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Glutamate ionotropic receptor NMDA type subunit 2A (Aging medicine (Milton (N.S.W)) · 2019Article
- Gene-by-environment interactions in Alzheimer's disease and Parkinson's disease.Neuroscience and biobehavioral reviews · 2019Review
- Interaction between caffeine and polymorphisms of glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) and cytochrome P450 1A2 (CYP1A2) on Parkinson's disease risk.Movement disorders : official journal of the Movement Disorder Society · 2018Article
- The Search for Environmental Causes of Parkinson's Disease: Moving Forward.Journal of Parkinson's disease · 2018Review
- Caffeine, creatine, GRIN2A and Parkinson's disease progression.Journal of the neurological sciences · 2017Article
- [Epidemiology and causes of Parkinson's disease].Der Nervenarzt · 2017Review
- Gene-Environment Interaction in Parkinson's Disease: Coffee, ADORA2A, and CYP1A2.Neuroepidemiology · 2016Article
- Genetic Profile, Environmental Exposure, and Their Interaction in Parkinson's Disease.Parkinson's disease · 2016Review
- Glutamate receptor gene GRIN2A, coffee, and Parkinson disease.PLoS genetics · 2014Article
Corrections and comments
- Commented on by
Authors and funding
22 authors at 14 institutions in 6 countries.
Ismaïl AhmedINSERM, Centre for research in Epidemiology and Population Health, U1018, Biostatistics team, Villejuif, France; Univ Paris-Sud, UMRS 1018, Paris, Villejuif, France.
Pei-Chen LeeDepartment of Health Care Management, College of Healthcare Administration and Management, National Taipei University of Nursing Health Sciences, Taipei, Taiwan.
Christina M LillDepartment of Vertebrate Genomics, Neuropsychiatric Genetics Group, Max Planck Institute for Molecular Genetics, Berlin, Germany; Department of Neurology, Focus Program Translational Neuroscience, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Susan Searles NielsenDepartment of Environmental and Occupational Health Sciences, University of Washington, Seattle, Washington, United States of America.
Fanny ArtaudINSERM, Centre for research in Epidemiology and Population Health, U1018, Social and occupational determinants of health, Villejuif, France; Univ de Versailles St-Quentin, UMRS 1018, Versailles, France.
Lisa G GallagherDepartment of Environmental and Occupational Health Sciences, University of Washington, Seattle, Washington, United States of America.
Marie-Anne LoriotAssistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Service de Biochimie, Paris, France; Université Paris Descartes, Inserm, UMR-S1147, Médecine personnalisée, Pharmacogénomique et optimisation thérapeutique, Paris, France.
Claire MulotUniversité Paris Descartes, Inserm, UMR-S1147, Médecine personnalisée, Pharmacogénomique et optimisation thérapeutique, Paris, France; Centre de ressources biologiques (CRB) Epigenetec, Paris, France.
Magali NacferUniversité Paris Descartes, Inserm, UMR-S1147, Médecine personnalisée, Pharmacogénomique et optimisation thérapeutique, Paris, France; Centre de ressources biologiques (CRB) Epigenetec, Paris, France.
Tian LiuMax Planck Institute for Human Development, Berlin, Germany.
Joanna M BiernackaDepartment of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United States of America.
Sebastian ArmasuDepartment of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United States of America.
Kari AndersonDepartment of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United States of America.
Federico M FarinDepartment of Environmental and Occupational Health Sciences, University of Washington, Seattle, Washington, United States of America.
Christina Funch LassenDanish Cancer Society Research Center, Danish Cancer Society, Copenhagen, Denmark.
Johnni HansenDanish Cancer Society Research Center, Danish Cancer Society, Copenhagen, Denmark.
Jørgen H OlsenDanish Cancer Society Research Center, Danish Cancer Society, Copenhagen, Denmark.
Lars BertramDepartment of Vertebrate Genomics, Neuropsychiatric Genetics Group, Max Planck Institute for Molecular Genetics, Berlin, Germany; Department of Medicine, School of Public Health, Imperial College London, London, United Kingdom.
Demetrius M MaraganoreDepartment of Neurology, NorthShore University HealthSystem, Evanston, Illinois, United States of America.
Harvey CheckowayDepartment of Family and Preventive Medicine, University of California, San Diego, La Jolla, California, United States of America.
Beate RitzDepartment of Epidemiology, Fielding School of Public Health, University of California Los Angeles, Los Angeles, California, United States of America.
Alexis ElbazINSERM, Centre for research in Epidemiology and Population Health, U1018, Social and occupational determinants of health, Villejuif, France; Univ de Versailles St-Quentin, UMRS 1018, Versailles, France.
Danish Cancer Society · DKMayo Clinic in Florida · USUniversity of Washington · USInserm · FRUniversité Paris Cité · FRAssistance Publique – Hôpitaux de Paris · FRCentre de recherche en Epidémiologie et Santé des Populations · FRMax Planck Institute for Human Development · DEMax Planck Institute for Molecular Genetics · DEMinistry of Health and Welfare · TWNorthShore University HealthSystem · USUniversity Medical Center of the Johannes Gutenberg University Mainz · DEUniversity of California, Los Angeles · USUniversity of California San Diego · US
Funding
WILDLIFE BIOMARKER APPLICATIONS TO REMEDIATION DECISION MAKINGP42ES004696 · NIEHS · UNIVERSITY OF WASHINGTON · PI FURLONG, CLEMENT EUGENE · 1987 to 2021
$51.2MXENOBIOTIC BIOTRANSFORMATION AND DISPOSITIONP30ES007033 · NIEHS · UNIVERSITY OF WASHINGTON · PI Sheela Sathyanarayana · 1995 to 2026
$42.5MSupplement-ES10751 (Molecular Epidemiology of PD)R01ES010751 · NIEHS · MAYO CLINIC ROCHESTER · PI MARAGANORE, DEMETRIUS MICHAEL · 2000 to 2010
$9.2MPARKINSON'S DISEASES SUSCEPTIBILITY GENES AND PESTICIDESR01ES010544 · NIEHS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RITZ, BEATE R. · 2000 to 2015
$5.7MRegistry Study of Parkinsons Disease in DenmarkR01ES013717 · NIEHS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RITZ, BEATE R. · 2006 to 2010
$4.5MNIEHS NIH HHS P30 ES007033NIEHS NIH HHS P30ES007033NIEHS NIH HHS P42 ES004696NIEHS NIH HHS P42ES004696NIEHS NIH HHS R01 ES010544NIEHS NIH HHS R01ES010544NIEHS NIH HHS R01 ES010751NIEHS NIH HHS R01 ES013717NIEHS NIH HHS R01ES013717NIEHS NIH HHS R01ES10751
Abstract
PubMed holds no abstract for this paper.
Indexed as
Gene-Environment InteractionGenome-Wide Association StudyCaffeineCoffeeDenmarkDNA ReplicationGenotypeHumansParkinson DiseasePolymorphism, Single NucleotideReceptors, N-Methyl-D-AspartateSmokingCaffeineCoffeeReceptors, N-Methyl-D-Aspartate
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.